Xbrane Biopharma has announced the initiation of developing two new biosimilar candidates referencing Keytruda and Darzalex respectively.
Together with the continued development of Xdivane, a biosimilar candidate referencing Opdivo, this forms an oncology biosimilar portfolio addressing 23 billion EUR of combined annual reference product sales, states the company.
Keytruda and Darzalex biosimilars
Keytruda is a PD1 inhibitor used in oncology treatment with annual sales of 13 billion EUR. Darzalex is a CD38 inhibitor used in the treatment of Multiple Myeloma with annual sales of 3.8 billion EUR. Together with Xdivane, these new biosimilar candidates form an oncology biosimilar portfolio targeting 23 billion EUR combined in annual reference product sales, which could be launched in 2028-2029 when the respective patents expire.
“Together with Xdivane, these new biosimilar candidates form an oncology biosimilar portfolio targeting 23 billion EUR combined in annual reference product sales.”
Accelerate the development
With the development of Xdivane, Xbrane has expanded its high-yield protein expression platform into mammalian cells, resulting in five recently approved patents. Xbrane will leverage this platform for the upcoming programs with the aim of getting the lowest production costs amongst competing biosimilars on the market, it states.
“With our high-yield platform technology, experienced team, and recently established development lab, we believe we are well positioned to accelerate the development of our portfolio. The development of this oncology biosimilar portfolio poses a real opportunity for us to make a sizable difference and to improve the accessibility of critical oncology products for millions of patients world-wide,” says Martin Åmark, CEO of Xbrane.
Photo of Martin Åmark: Xbrane